• Active, not recruiting

NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard Regimens NDMM

Updated: Sep 10


NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

tak-079


NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)


The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen. The purpose of the safety/access cohort is to provide continued access to TAK-079 to participants previously enrolled to a TAK-079 parent study and to evaluate the long-term safety profile of TAK-079.


Sponsor:

Takeda

 

ClinicalTrials.gov Identifier: NCT03984097

Official Title: An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy

First Posted : June 12, 2019

Click here to see details on ClinicalTrials.gov

 

Drug: TAK-079

Drug: Lenalidomide

Drug: Dexamethasone

Drug: Bortezomib

Drug: Pomalidomide

 

TAK-079


Mezagitamab (Code C148078)

Anti-CD38 MAb TAK-079

Mezagitamab

MEZAGITAMAB

TAK 079

TAK-079

TAK079

 

Locations

United States, Alabama

United States, California

United States, Maryland

United States, New York

United States, North Carolina

United States, Ohio

United States, Oregon

United States, Texas

United States, Wisconsin





Posts Archive